Professor John Simes is a Senior Principal Research Fellow, Director of the CTC and Co-director of Cancer at CTC.

John is a leading international researcher in clinical trials, particularly in cancer, cardiovascular disease, diabetes and neonatal medicine. He co-leads the CTC's team of 200 who collaborate with clinical investigators and other researchers nationally and internationally in a research program aimed at improving health practice and health outcomes through better use of clinical trials research. He has contributed to over 300 peer-reviewed articles, with many having a significant impact on current knowledge and clinical practice.

John is the Founding Director and a current board member of the Sydney Catalyst Translational Research Centre, a virtual centre of cancer researchers in central Sydney and regional NSW. He is a founding member of the Australian Clinical Trials Alliance (ACTA), formed in 2012 to promote effective and evidence based healthcare in Australia through investigator-initiated clinical trials.

John is a practising medical oncologist in neuro-oncology at Royal Prince Alfred Hospital and the Chris O'Brien Lifehouse, and is professor of clinical epidemiology, Faculty of Medicine, University of Sydney. He has taught medical students and postgraduate students at the University of Sydney since 1989. He was awarded the Cancer Achievement Award for lifetime achievement in oncology by the Medical Oncology Group of Australia (2010) and the Distinguished Harvard Alum Award (Biostatistics) from Harvard University (2009) in recognition of his work in research. He has recently been elected as a Fellow of the Australian Academy of Health and Medical Sciences. He is a member of research committees, trials groups and boards, including cancer cooperative groups and safety and data monitoring committees. He has recently been elected as a Fellow of the Australian Academy of Health and Medical Sciences and was named on the Clarivate Analytics 2018 Highly Cited Researchers List for 2018

Committee Memberships:

• Australian Clinical Trials Alliance boardNHMRC CTC Research Committee
• ANZ Clinical Trials Registry Advisory Committee
• Management Committee, Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID)
• Management Committee and Executive, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD)
• Joint coordinator, Cholesterol Treatment Trialists Collaboration (CTTC)
• Steering Committee chair, International Trials of Aspirin to Prevent Recurrent Venous Thrombo-embolism (INSPIRE)
• Safety and Data Monitoring Committee, Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)
• Scientific Advisory Committee, ANZ Breast Cancer Trials Group (ANZBCTG)
• Scientific Advisory Committee, Australasian Gastro-Intestinal Trials Group (AGITG) (group coordinator since 2002)
• Scientific Advisory Committee, Cooperative Trials Group for Neuro-Oncology (COGNO) (deputy chair)
• Trial Management Committee, Sentinel Biopsy versus Axillary Clearance trial (SNAC)
• Trial Management Committee, Aspirin to Prevent Recurrent Venous Thrombo-embolism (ASPIRE) (chair)
• Trial Management Committee, Benefits Of Oxygen Saturation Targeting (BOOST II)
• Trial Management Committee, Lactoferrin Infant Feeding Trial (LIFT)
• Trial Management Committee, Individualised Molecular Pancreatic Cancer Therapy (IMPACT) (co-chair)

Publications

View John's publications.